Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A genome-wide CRISPR/Cas9 screen identifies DNA-PK as a sensitiser to 177 Lutetium-DOTA-octreotate radionuclide therapy

1 Jan 2023

Abstract excerpt

Peptide receptor radionuclide therapy (PRRT) using 177 Lutetium-DOTA-octreotate (LuTate) for neuroendocrine tumours (NET) is now an approved treatment available in many countries, though primary or secondary resistance continue to limit its effectiveness or durability. We hypothesised that a genome-wide CRISPR/Cas9 screen would identify key mediators of response to LuTate and gene targets that might offer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Research Studies
Share to Neuroblastoma Research and Treatments
Share to Neuroendocrine Tumor Research Advances

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37771787
DOI: 10.7150/thno.84628

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A genome-wide CRISPR/Cas9 screen identifies DNA-PK as a sensitiser to 177 Lutetium-DOTA-octreotate radionuclide therapyPMID 37771787Read ↗

Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapySemantic proximity Read ↗

Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARPSemantic proximity Read ↗

MYC predetermines the sensitivity of gastrointestinal cancer to antifolate drugs through regulating TYMS transcriptionSemantic proximity Read ↗

DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivoSemantic proximity Read ↗

A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing-tumor as a potential target of peptide receptor imaging and therapySemantic proximity Read ↗

Upregulation of Somatostatin Receptor Type 2 in a Receptor-Deficient <i>In Vivo</i> Pancreatic Neuroendocrine Tumor Model Improves Tumor Response to Targeted <sup>177</sup> Lu-DOTATATESemantic proximity Read ↗

Somatostatin Receptor Based Imaging and Radionuclide TherapySemantic proximity Read ↗

Profiling proteomic responses in small intestinal neuroendocrine tumor GOT1 after [177Lu]Lu-DOTATATE therapySemantic proximity Read ↗

Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Advanced Neuroendocrine Tumours (NETs) in a Limited Resource EnvironmentSemantic proximity Read ↗

The Biology of the Sodium Iodide Symporter and its Potential for Targeted Gene DeliverySemantic proximity Read ↗

The sodium iodide symporter (NIS): novel applications for radionuclide imaging and treatmentSemantic proximity Read ↗

Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.